Healthcare

The interest is not only about scale. Ramsay sits at the meeting point of long-term demand for healthcare services, the economics of running large hospital networks, and the broader pressures facing the sector. For investors trying to gauge the health of defensive, demand-driven businesses …

The appeal of Sonic lies in its scale, international diversification and exposure to the steady, structural demand for diagnostic services. For investors weighing the opportunity, the company presents the profile of a defensive healthcare business navigating a transition, balanced against pressures on margins, funding …

• Phase 3 clinical development remains a major focus for investors.

The attention paid to Medibank extends beyond the health-insurance industry. As a significant company on the Australian Securities Exchange, its share-price behaviour is frequently read as a signal about appetite for defensive earnings and the dynamics of the private health sector. This article examines …

What sets Pro Medicus apart is the combination of a focused product, a high-margin recurring revenue model and exposure to the structural demand for advanced medical imaging. As the company has expanded its presence, particularly among large healthcare institutions, it has drawn attention as …

Imugene Limited (ASX:IMU) sits in one of the most closely followed and most volatile corners of the local market: clinical-stage cancer therapeutics. Companies in this space rarely carry meaningful revenue, so each trial update functions as both a scientific milestone and a referendum on …

Aroa Biosurgery (ASX:ARX) has rounded out its 2026 financial year with one of the strongest results in its listed history, lifting revenue past NZ$100 million, generating positive net cash and sharply expanding its normalised earnings. With guidance pointing to further growth in the year …